Background: The prevalence of nausea and vomiting after receipt of intrathecal methotrexate (IT-MTX) in pediatric oncology patients is unknown.
INTRODUCTION
Chemotherapy emetogenicity is the primary factor considered when selecting chemotherapy-induced nausea and vomiting (CINV) prophylaxis for children. 1 Yet, the CINV experience of children and adolescents receiving specific chemotherapy is seldom documented. To date, no publications have evaluated nausea and vomiting in pediatric patients exclusively receiving intrathecal methotrexate (IT-MTX), a required component of acute lymphoblastic leukemia (ALL) treatAbbreviations: ALL, acute lymphoblastic leukemia; CIN, chemotherapy-induced nausea; CINV, chemotherapy-induced nausea and vomiting; CIV, chemotherapy-induced vomiting;
IT-MTX, intrathecal methotrexate; IV, intravenous; PeNAT, Pediatric Nausea Assessment Tool; PO, oral; TIT, triple intrathecal therapy ment. Without this information, it is difficult to apply the recommendations of clinical practice guidelines for the prevention of CINV 2, 3 and to optimize CINV control. In this study, we used a validated, pediatric nausea self-assessment measure the (PeNAT) 4 to describe the prevalence of acute and delayed CINV in pediatric patients with ALL receiving IT-MTX.
METHODS
This prospective, single-center, observational study was approved by the Research Ethics Board at SickKids. Each patient or their guardian provided informed consent or assent to study participation. 
TA B L E 1 CINV study endpoints

Data collection
Patient's demographic data, chemotherapy and antiemetic agents given in hospital or clinic during the study period, and medication given during the lumbar puncture procedure were abstracted from the health record. Patients or their parent were asked if they had a history of uncontrolled chemotherapy-induced vomiting (CIV) defined as a previous hospital admission or the prolongation of a hospital admission for management of vomiting following chemotherapy administration. Antiemetic medication given at home during the study period was recorded by the patient or parent on a diary provided. A member of the study team contacted each family up to three times during the study period to answer any questions and to remind them to complete and return the diary.
CINV assessment
Statistical analysis
The primary endpoint of this descriptive study was complete control of CINV during the acute phase ( Differences between groups were assessed using chi-square or nonparametric analyses as appropriate (SAS Enterprise Guide 6.100, SAS Institute Inc., Cary, NC, USA).
RESULTS
Patients
Two hundred four patients were screened from May 7, 2012, through October 2, 2015, and 124 were invited to participate in the study.
Of the 88 patients who initiated the study, 70 returned completed diaries. Patients who did not return completed diaries did not differ from patients who did return completed diaries in terms of mean age (7.6 ± 4.2 vs. 8.3 ± 3.3 years; P = 0.14) or sex (female/male: 5/13 vs.
19/51; P = 0.23). The study flow diagram is presented in Figure 1 .
Patient and treatment characteristics are presented in Table 2 . 
CINV Control
CINV, CIV, and CIN control rates reported in the acute, delayed, and overall phases are presented in Table 3 . During the acute phase, 36 patients (51%) experienced complete CINV control, 67 (96%) complete vomiting control, and 36 (51%) complete nausea control. Severe acute nausea was reported by 12 children (17%). In the delayed phase, 35 children (50%) experienced complete CINV control, 60 (86%) complete vomiting control, and 36 (51%) complete nausea control. Severe nausea was reported in the delayed phase by 27 (39%) children.
DISCUSSION
In this prospective study, we found that pediatric patients who MTX, and hydrocortisone) to pediatric patients. 6, 7, 10 In the first, vomiting was evaluated in a subset of 16 patients after 27 doses of TIT where no antiemetic prophylaxis had been given. 10 The mean number of vomiting episodes reported in the 7 days after TIT administration in this subset was 8.3 ± 12.2. The same authors later described vomiting control in 63 patients aged 1-17 years who received TIT. 6 Since all patients in our population were older than 3 years and we did not have information relating to familial history, we could not explore these relationships.
TA B L E 2 Characteristics of the 70 evaluable patients and their treatment
The rate of complete acute CIV control observed in our study was higher than has been reported in children receiving dexamethasone or ondansetron prior to intrathecal chemotherapy administration. Differences may be due, at least in part, to the anesthetic agent (e.g., propofol vs. ketamine). For example, propofol has a very low emetic risk and is, therefore, the preferred anesthetic for patients at high risk of postoperative vomiting. 11 In addition, unlike other studies where patients received a single ondansetron dose, several patients in our study received more than one ondansetron dose during the acute phase. The corticosteroid administered as part of the leukemia treatment may also have conveyed an antiemetic effect. It is also possible FLANK ET AL.
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that specific chemotherapy agents may be more or less emetogenic than MTX.
Interpretation of our study findings regarding CINV in the delayed phase following IT-MTX administration is limited by the administration of PO chemotherapy during this period. Although the rates of vomiting and nausea reflect the experience of our patients, symptoms are likely attributable to both IT-MTX and PO chemotherapy. Furthermore, participation in our study may have been subject to selection bias; it is possible that patients may have been more or less apt to participate depending on their prior experience with CINV.
In conclusion, acute phase CIV control in children receiving IT-MTX with propofol anesthesia and ondansetron or granisetron is excellent.
Our study, the first to use a validated, pediatric, self-report measure to evaluate nausea severity in children receiving intrathecal chemotherapy, found that severe nausea is a common experience of children who receive IT-MTX. Effective antinausea interventions must be identified to optimize CINV control in children.
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